The anticoagulant has $137 million in annual sales in the US.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) today obtained tentative approval from the US Food and Drug Administration (FDA) for the company's Abbreviated New Drug Application (ANDA) to market a generic version of Argatroban, an anticoagulant made by GlaxosmithKline plc (NYSE; LSE: GSK).
Brand sales of Argatroban in the US amount to $137 million, according to IMS sales data.
Teva added that a bench trial in an ongoing patent litigation was completed in the US District Court for the Southern District of New York in February.
Teva's share price fell 0.3% at the opening on Nasdaq today to $63.91. The share price fell 1.1% on the TASE today.
Published by Globes [online], Israel business news - www.globes-online.com - on March 25, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010